CysLT1 receptor Inhibitors
1 drugsAbout CysLT1 receptor
The cysteinyl leukotriene receptor 1 (CysLT1) is a G protein-coupled receptor involved in inflammatory responses, especially in the respiratory system. It mediates the effects of leukotrienes, leading to bronchoconstriction, mucus production, and airway inflammation.
As a clinically validated target, CysLT1 receptor antagonism alleviates symptoms of asthma and allergic rhinitis. Currently, there is no genetic evidence available linking CysLT1 to specific diseases, warranting further investigation into its genetic associations.
CysLT1 is targeted by one FDA-approved drug, SINGULAIR (montelukast), a small molecule used for respiratory diseases. Merck is the primary company in this space, having developed SINGULAIR, which was first approved in 1998.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Carcinoma, Non-Small-Cell Lung with only 1 trials.
Top CysLT1 receptor Drugs
Merck is the leading company with the only approved drug, SINGULAIR, targeting CysLT1.
High market concentration suggests significant entry barriers; consider strategic partnerships to compete effectively.
CysLT1 receptor Clinical Trials 95 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 24 | 22 | 1 | 1 | 96% |
| Phase 2 | 29 | 20 | 1 | 8 | 95% |
| Phase 3 | 16 | 10 | 3 | 3 | 77% |
| Phase 4 | 26 | 20 | 2 | 3 | 91% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 49 clinical trials targeting CysLT1 receptor.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities